Breaking News Out !!!
Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
BEVERLY, MA – October 9, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that it has secured new financing for up to $10 million from one multi-family office focused on healthcare and life sciences, including an initial net placement of approximately $2.2 million over the first 30 days. These funds will be used to continue to advance the Company’s pipeline of first-in-class drug candidates: Brilacidin for Oral Mucositis, Kevetrin for Ovarian Cancer and Prurisol for Psoriasis.
The Company entered into a Securities Purchase Agreement pursuant to which the Company agreed to sell preferred stock that is convertible to its Class A common stock and warrants in a registered direct offering (the “Offering”), without an underwriter or placement agent. The first tranche of the Offering is anticipated to close on October 9, 2018. For additional information about the Securities Purchase Agreement, refer to the current report on Form 8-K filed on October 9, 2018 with the Securities and Exchange Commission.
The Offering was registered pursuant to the Company’s effective Shelf Registration Statement on Form S-3 (File No. 333-220419) (the “Registration Statement”) and the related base prospectus included in the Registration Statement, as supplemented by the prospectus supplement dated October 5, 2018.
“This new financing serves to further bolster our balance sheet and gives us flexibility in working to meet our near-term goals, which includes advancing Brilacidin into a pivotal study,” said Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals. “The Company is at an exciting juncture, with our three novel drug candidates successfully reaching mid- and later-stage trials across multiple indications representing large market opportunities. We remain steadfast in delivering innovative medicines to patients and increasing the Company’s valuation.”
Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
BEVERLY, MA – October 9, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that it has secured new financing for up to $10 million from one multi-family office focused on healthcare and life sciences, including an initial net placement of approximately $2.2 million over the first 30 days. These funds will be used to continue to advance the Company’s pipeline of first-in-class drug candidates: Brilacidin for Oral Mucositis, Kevetrin for Ovarian Cancer and Prurisol for Psoriasis.
The Company entered into a Securities Purchase Agreement pursuant to which the Company agreed to sell preferred stock that is convertible to its Class A common stock and warrants in a registered direct offering (the “Offering”), without an underwriter or placement agent. The first tranche of the Offering is anticipated to close on October 9, 2018. For additional information about the Securities Purchase Agreement, refer to the current report on Form 8-K filed on October 9, 2018 with the Securities and Exchange Commission.
The Offering was registered pursuant to the Company’s effective Shelf Registration Statement on Form S-3 (File No. 333-220419) (the “Registration Statement”) and the related base prospectus included in the Registration Statement, as supplemented by the prospectus supplement dated October 5, 2018.
“This new financing serves to further bolster our balance sheet and gives us flexibility in working to meet our near-term goals, which includes advancing Brilacidin into a pivotal study,” said Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals. “The Company is at an exciting juncture, with our three novel drug candidates successfully reaching mid- and later-stage trials across multiple indications representing large market opportunities. We remain steadfast in delivering innovative medicines to patients and increasing the Company’s valuation.”
1
